2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. (September 2015) - Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; et al.